×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CAPR – capricor therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CAPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/14
08:42 am
capr
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/10
04:37 am
capr
Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]
Low
Report
Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]
1/9
06:31 am
capr
Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]
Medium
Report
Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]
12/18
01:32 pm
capr
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
Low
Report
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
12/16
04:05 pm
capr
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
Low
Report
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
12/15
10:04 am
capr
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
04:01 pm
capr
capricor therapeutics, inc.
IN-LINE
Report
11.9%
capricor therapeutics, inc.
8/11/2025
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
-0.1%
capricor therapeutics, inc.
5/13/2025
04:05 pm
capr
capricor therapeutics, inc.
MISS
Report
1.1%
capricor therapeutics, inc.
3/19/2025
04:05 pm
capr
capricor therapeutics, inc.
BEAT
Report
15.6%
capricor therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Litvack Frank
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Litvack Frank
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Marban Linda
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Marban Linda
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Musket David B
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Musket David B
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Auwaerter Paul Gisbert
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Auwaerter Paul Gisbert
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Gotwals Philip J
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Gotwals Philip J
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: DUNBAR GEORGE W JR
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: DUNBAR GEORGE W JR
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Bergmann Anthony
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Bergmann Anthony
1/7
04:45 pm
capr
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Sabar Karimah Es
Medium
Report
Form 4 CAPRICOR THERAPEUTICS, For: Jan 05 Filed by: Sabar Karimah Es
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
251.2%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%
3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%
3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%
9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%
3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%
4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%
9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%
10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%
12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%
TOP News Decliners
4/3
Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
-37.5%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%
7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%
10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%
7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%
11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%
12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%
7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: